Cargando…

Research Progress on Catalpol as Treatment for Atherosclerosis

Coronary atherosclerotic heart disease, cerebrovascular disease, and peripheral artery disease are common diseases with high morbidity and mortality rates and must be addressed. Their most frequent complications, including myocardial infarction and stroke, are caused by spontaneous thrombotic occlus...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Lei, Zhao, Rusheng, Wang, Youheng, Liu, Huibing, Wang, Xuehui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313760/
https://www.ncbi.nlm.nih.gov/pubmed/34326774
http://dx.doi.org/10.3389/fphar.2021.716125
_version_ 1783729412783472640
author He, Lei
Zhao, Rusheng
Wang, Youheng
Liu, Huibing
Wang, Xuehui
author_facet He, Lei
Zhao, Rusheng
Wang, Youheng
Liu, Huibing
Wang, Xuehui
author_sort He, Lei
collection PubMed
description Coronary atherosclerotic heart disease, cerebrovascular disease, and peripheral artery disease are common diseases with high morbidity and mortality rates and must be addressed. Their most frequent complications, including myocardial infarction and stroke, are caused by spontaneous thrombotic occlusion and are the most frequent cause of death worldwide. Atherosclerosis (AS) is the most widespread underlying pathological change for the above diseases. Therefore, drugs that interfere with this pathophysiological process must be incorporated in the treatment. Chinese traditional and herbal drugs can effectively treat AS. With the development of traditional Chinese medicine, the active ingredients in common Chinese medicinal materials must be thoroughly purified prior to their application in western medicine. Various proprietary Chinese medicine preparations with remarkable effects have been used in AS treatment. Catalpol, the active component of Rehmannia glutinosa, belongs to iridoid terpene and has anti-inflammatory, antioxidant, insulin resistance improvement, and other related effects. Several reviews have been conducted on this compound and its actions against osteoporosis, neurodegenerative diseases, Alzheimer's disease (AD), Parkinson's disease (PD) and diabetes and its complications. The current review focused on catalpol’s effect on atherosclerotic plaque formation in different animal models. The potential mechanisms of catalpol to ameliorate AS were also summarized in terms of oxidative stress, inflammation, cell aging, apoptosis, and activation of the silent information regulator factor 2-related enzyme 1 (SIRT1) pathway.
format Online
Article
Text
id pubmed-8313760
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83137602021-07-28 Research Progress on Catalpol as Treatment for Atherosclerosis He, Lei Zhao, Rusheng Wang, Youheng Liu, Huibing Wang, Xuehui Front Pharmacol Pharmacology Coronary atherosclerotic heart disease, cerebrovascular disease, and peripheral artery disease are common diseases with high morbidity and mortality rates and must be addressed. Their most frequent complications, including myocardial infarction and stroke, are caused by spontaneous thrombotic occlusion and are the most frequent cause of death worldwide. Atherosclerosis (AS) is the most widespread underlying pathological change for the above diseases. Therefore, drugs that interfere with this pathophysiological process must be incorporated in the treatment. Chinese traditional and herbal drugs can effectively treat AS. With the development of traditional Chinese medicine, the active ingredients in common Chinese medicinal materials must be thoroughly purified prior to their application in western medicine. Various proprietary Chinese medicine preparations with remarkable effects have been used in AS treatment. Catalpol, the active component of Rehmannia glutinosa, belongs to iridoid terpene and has anti-inflammatory, antioxidant, insulin resistance improvement, and other related effects. Several reviews have been conducted on this compound and its actions against osteoporosis, neurodegenerative diseases, Alzheimer's disease (AD), Parkinson's disease (PD) and diabetes and its complications. The current review focused on catalpol’s effect on atherosclerotic plaque formation in different animal models. The potential mechanisms of catalpol to ameliorate AS were also summarized in terms of oxidative stress, inflammation, cell aging, apoptosis, and activation of the silent information regulator factor 2-related enzyme 1 (SIRT1) pathway. Frontiers Media S.A. 2021-07-13 /pmc/articles/PMC8313760/ /pubmed/34326774 http://dx.doi.org/10.3389/fphar.2021.716125 Text en Copyright © 2021 He, Zhao, Wang, Liu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
He, Lei
Zhao, Rusheng
Wang, Youheng
Liu, Huibing
Wang, Xuehui
Research Progress on Catalpol as Treatment for Atherosclerosis
title Research Progress on Catalpol as Treatment for Atherosclerosis
title_full Research Progress on Catalpol as Treatment for Atherosclerosis
title_fullStr Research Progress on Catalpol as Treatment for Atherosclerosis
title_full_unstemmed Research Progress on Catalpol as Treatment for Atherosclerosis
title_short Research Progress on Catalpol as Treatment for Atherosclerosis
title_sort research progress on catalpol as treatment for atherosclerosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313760/
https://www.ncbi.nlm.nih.gov/pubmed/34326774
http://dx.doi.org/10.3389/fphar.2021.716125
work_keys_str_mv AT helei researchprogressoncatalpolastreatmentforatherosclerosis
AT zhaorusheng researchprogressoncatalpolastreatmentforatherosclerosis
AT wangyouheng researchprogressoncatalpolastreatmentforatherosclerosis
AT liuhuibing researchprogressoncatalpolastreatmentforatherosclerosis
AT wangxuehui researchprogressoncatalpolastreatmentforatherosclerosis